Report On Bristol Myers Squibb Co (NYSE:BMY) Healthcare Sector Stock
Bristol Myers Squibb Co (NYSE:BMY) is a global biopharmaceutical company, discovers, develops, and delivers innovative medicines that help patients prevail over serious diseases. The company focuses on areas of serious unmet medical needs, such as cardiovascular disease, mental illness, cancer, HIV/AIDS, hepatitis B and C, rheumatoid arthritis, type 2 diabetes, solid organ transplantation, and Alzheimer’s disease. Its principal products include PLAVIX for protection against fatal or non-fatal heart attack or stroke; AVAPRO/AVALIDE for the treatment of hypertension and diabetic nephropathy; ABILIFY, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and REYATAZ for the treatment of HIV. The company’s principal products also comprise SUSTIVA for the treatment of HIV; BARACLUDE, an inhibitor of hepatitis B virus; ERBITUX to target and block the epidermal growth factor receptor; SPRYCEL for treatment of chronic myeloid leukemia in adults; IXEMPRA to treat breast cancer; ORENCIA to severe rheumatoid arthritis in adults; and ONGLYZA for the treatment of type 2 diabetes. Its products under Phase III clinical trials include ELIQUIS to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; NULOJIX to prevent solid organ transplant rejection; Brivanib to block the VEGF and the FGF receptors; Dapagliflozin to treat diabetes; YERVOY to treat metastatic melanoma; and Necitumumab for anticancer treatment. The company sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances with sanofi-aventis; Pfizer, Inc.; AstraZeneca PLC; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; and Gilead Sciences, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Bristol Myers Squibb Co (NYSE:BMY)
BMY vs. Industry Leaders
Statistic Industry Leaders BMY BMY Ranked
| Market Capitalization | PFZ.L | 169.62B | 56.37B | 30 / 180 |
| P/E Ratio (ttm) | DPH.L | 2,420.19 | 15.46 | 41 / 180 |
| PEG Ratio (ttm, 5 yr expected) | AZN | 6.01 | 12.37 | 31 / 180 |
| Revenue Growth (Qtrly YoY) | TRABI.BO | 761.50% | 6.70% | 57 / 180 |
| EPS Growth (Qtrly YoY) | MRK | N/A | 78.10% | 54 / 180 |
| Long-Term Growth Rate (5 yr) | PVCT.OB | 116.00% | 1.37% | N/A |
| Return on Equity (ttm) | RHO5.DE | 73.01% | 33.39% | 13 / 180 |
| Long-Term Debt/Equity (mrq) | 34.606 | N/A | ||
| Dividend Yield (annual) | GSK | 5.80% | 4.10% | 4 / 180 |
Bristol Myers Squibb Co (NYSE:BMY) generated the revenue of $5.45 billion for the quarter ended December 31st, 2011 as compared to revenue of $5.11 billion for the same period last year. The company reported the net profit of $852 million or earnings of $0.54 per share for the respective quarter as compared to net income of $483 million or earnings of $0.47 per share last year.
The company’s total assets accumulate up to $32.97 billion out of which fixed assets have the highest proportion. The company maintains a strong short term liquidity position as per its current ratio of 1.97 times.
← Review On Boston Scientific Corporation (NYSE:BSX) Analytic Report On Baxter International Inc (NYSE:BAX) →
